GlassScriptPhysician profile
Shontae Howard
NPI 1255531315
$2,943.54
in general payments reported to CMS, 2019-2025
21 companies · $2,251 in 2025
The $2,251 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $142 · 2022: $19.17 · 2023: $169 · 2024: $361 · 2025: $2,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,782.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $462.33 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $391.46 | 2024-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $333.73 | 2023-2025 | |
| Lundbeck LLC | $251.72 | 2024-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $230.51 | 2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $207.77 | 2024-2025 | Austedo Xr, Uzedy |
| Indivior INC. | $172.28 | 2024-2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $138.40 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $138.11 | 2025 | Cobenfy |
| Uswm, LLC | $126.82 | 2022-2024 | Lucemyra, Zimhi |
| Collegium Pharmaceutical, INC. | $100.96 | 2021 | |
| Axsome Therapeutics, INC. | $95.44 | 2023-2025 | Auvelity, Symbravo |
| Neurocrine Biosciences, INC. | $76.83 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.67 | 2025 | Caplyta |
| Noven Therapeutics, LLC | $36.07 | 2025 | Xelstrym, Secuado |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $30.93 | 2023-2025 | Quviviq, Quviviq |
| Supernus Pharmaceuticals, INC. | $21.60 | 2025 | Qelbree |
| Amgen INC. | $21.46 | 2021 | |
| Tersera Therapeutics LLC | $19.95 | 2021 | |
| Tris Pharma INC | $14.38 | 2025 | Dyanavel Xr |
| Tonix Medicines, INC. | $14.12 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shontae Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.